Columbus Circle Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Columbus Circle Investors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-89,132	Closed	-$5.59M	–	252
2016 Q1	$5.59M	Buy	89,132 +47,170	+112%	+$3.14M	0.05%	208
2015 Q4	$3.95M	Sell	41,962 -40,782	-49%	-$3.78M	0.03%	231
2015 Q3	$6.65M	Sell	82,744 -256,787	-76%	-$28.5M	0.05%	215
2015 Q2	$40.7M	Buy	339,531 +49,971	+17%	+$5.97M	0.29%	89
2015 Q1	$30.2M	Sell	289,560 -84,488	-23%	-$8.56M	0.21%	114
2014 Q4	$36.3M	Sell	374,048 -197,204	-35%	-$18.3M	0.26%	92
2014 Q3	$44.6M	Sell	571,252 -149,584	-21%	-$9.65M	0.32%	82
2014 Q2	$45.5M	Sell	720,836 -283,509	-28%	-$16.9M	0.31%	90
2014 Q1	$67.4M	Buy	1,004,345 +346,036	+53%	+$26.8M	0.45%	64
2013 Q4	$42.3M	Sell	658,309 -300,008	-31%	-$17.9M	0.29%	96
2013 Q3	$61.3M	Buy	958,317 +342,395	+56%	+$17.1M	0.43%	72
2013 Q2	$19.1M	Buy	+615,922	New	+$16.4M	0.15%	156

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Columbus Circle Investors's ALNY Position: Q2 2016 in Review

Columbus Circle Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2016, closing a stake of 89,132 shares — an estimated $5.59M sold.

Columbus Circle Investors first reported a position in ALNY in Q2 2013 and held it in 12 quarters. The position peaked at $67.4M in Q1 2014. 249 funds tracked by Wall St. Rank hold ALNY as of Q2 2016.

Columbus Circle Investors reported no remaining Alnylam Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Columbus Circle Investors sold 89,132 Alnylam Pharmaceuticals shares in Q2 2016, an estimated $5.59M.
Columbus Circle Investors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Columbus Circle Investors's Alnylam Pharmaceuticals position peaked at $67.4M in Q1 2014.
249 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2016.

Based on Columbus Circle Investors's 13F filing for Q2 2016, filed 2 Aug 2016.